Evidence map›Paper›PMID 33123557›Full record

ReviewERJ open research2020

Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Disease 2019.

Darcy E Wagner, Laertis Ikonomou, Sarah E Gilpin, Chelsea M Magin, Fernanda Cruz, Allison Greaney, Mattias Magnusson, Ya-Wen Chen, Brian Davis, Kim Vanuytsel and 9 more

Open access · goldAbstract readReview
In one paragraph

Review in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Stem cells, cell therapies, and bioengineering in lung biology and diseases 2023.American journal of physiology. Lung cellular and molecular physiology · 2024
    Review
  2. Stem cells, cell therapies, and bioengineering in lung biology and disease 2021.American journal of physiology. Lung cellular and molecular physiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 5 countries.

Darcy E WagnerLung Bioengineering and Regeneration, Dept of Experimental Medicine, Wallenberg Center for Molecular Medicine and Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.ORCID https://orcid.org/0000-0003-3794-1309
Laertis IkonomouCenter for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA, USA.
Sarah E GilpinWyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.ORCID https://orcid.org/0000-0003-3560-6910
Chelsea M MaginDepts of Medicine and Bioengineering, University of Colorado, Denver, Aurora, CO, USA.
Fernanda CruzFederal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Allison GreaneyDept of Biomedical Engineering, Yale University, New Haven, CT, USA.
Mattias MagnussonMolecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden.
Ya-Wen ChenHastings Center for Pulmonary Research, Dept of Medicine, University of Southern California, Los Angeles, CA, USA.
Brian DavisCenter for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, USA.
Kim VanuytselCenter for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA, USA.
Sara Rolandsson EnesDept of Medicine, University of Vermont, Burlington, VT, USA.
Anna KrasnodembskayaWellcome-Wolfson Research Institute, Queen's University Belfast, Belfast, UK.ORCID https://orcid.org/0000-0002-2380-5069
Mareike LehmannComprehensive Pneumology Center, Lung Repair and Regeneration Unit, Helmholtz Center Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-8601-8206
Gunilla Westergren-ThorssonDept of Experimental Medical Science, Division of Lung Biology, Lund University, Lund, Sweden.
John StegmayrLung Bioengineering and Regeneration, Dept of Experimental Medicine, Wallenberg Center for Molecular Medicine and Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.
Hani N AlsafadiLung Bioengineering and Regeneration, Dept of Experimental Medicine, Wallenberg Center for Molecular Medicine and Lund Stem Cell Center, Faculty of Medicine, Lund University, Lund, Sweden.
Evan T HoffmanDept of Medicine, University of Vermont, Burlington, VT, USA.
Daniel J WeissDept of Medicine, University of Vermont, Burlington, VT, USA.
Amy L RyanHastings Center for Pulmonary Research, Dept of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-1363-905X
Lund University · SEUniversity of Vermont · USBoston University · USUniversity of Southern California · USBrown Foundation · USHarvard University · USHelmholtz Zentrum München · DEQueen's University Belfast · GBUniversidade Federal do Rio de Janeiro · BRUniversity of Colorado Denver · USYale University · US

Funding

Stem Cells, Cell Therapies and Bioengineering in Lung Biology and DiseasesR13HL149436 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI WEISS, DANIEL J · 2019 to 2019
$30k
Medical Research Council MR/R025096/1Medical Research Council MR/S009426/1NHLBI NIH HHS R13 HL149436
6 · The paper itself

Abstract

A workshop entitled "Stem Cells, Cell Therapies and Bioengineering in Lung Biology and Diseases" was hosted by the University of Vermont Larner College of Medicine in collaboration with the National Heart, Lung and Blood Institute, the Alpha-1 Foundation, the Cystic Fibrosis Foundation, the International Society for Cell and Gene Therapy and the Pulmonary Fibrosis Foundation. The event was held from July 15 to 18, 2019 at the University of Vermont, Burlington, Vermont. The objectives of the conference were to review and discuss the current status of the following active areas of research: 1) technological advancements in the analysis and visualisation of lung stem and progenitor cells; 2) evaluation of lung stem and progenitor cells in the context of their interactions with the niche; 3) progress toward the application and delivery of stem and progenitor cells for the treatment of lung diseases such as cystic fibrosis; 4) progress in induced pluripotent stem cell models and application for disease modelling; and 5) the emerging roles of cell therapy and extracellular vesicles in immunomodulation of the lung. This selection of topics represents some of the most dynamic research areas in which incredible progress continues to be made. The workshop also included active discussion on the regulation and commercialisation of regenerative medicine products and concluded with an open discussion to set priorities and recommendations for future research directions in basic and translation lung biology.

Identifiers

PMID33123557
PMCPMC7569162
OpenAlexW3092905042

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.